01484nas a2200325   4500000000100000008004100001260001300042653001500055653001000070653001000080653002100090653001200111653001100123653001100134653001100145653001200156653000900168653001500177653001700192100001600209700001400225700001300239245010200252856005900354300001100413490000700424050003200431520068100463022001401144       1991                            d  c1991 Sep10aAdolescent10aAdult10aChild10aChild, Preschool10aDapsone10aFemale10aHumans10aInfant10aleprosy10aMale10aRecurrence10aRisk Factors1 aPandian T D1 aMuliyil J1 aVellut C00aRisk of relapse among non-lepromatous patients released from treatment after dapsone monotherapy.  uhttp://leprev.ilsl.br/pdfs/1991/v62n3/pdf/v62n3a07.pdf  a288-960 v62  aInfolep Library - available3 a<p>Information on 14,625 non-lepromatous patients released from treatment after dapsone monotherapy and followed up to a maximum of 15 years at the ILEP project. Dharmapuri, India, was analysed to study the pattern of relapses. The overall relapse rate was 5/1000 person years. Males had a higher relapse rate than females. The risk of relapse increased with age, number of lesions and duration of treatment. The risk for relapse remained constant over several years after release from treatment. Even though the absolute risk for relapse after MDT may be different, the pattern of relapses and the factors affecting it may be similar to what has been shown in this study.</p>  a0305-7518